(Q27011357)

V. Llorenç

series ordinal

3

1 reference

language of work or name

1 reference

June 2014

1 reference

Clinical and Experimental Immunology

published in

1 reference

volume

176

1 reference

issue

3

1 reference

page(s)

301-9

1 reference

Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

The danger model: a renewed sense of self

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Interleukin-17 and type 17 helper T cells

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Current and future treatments for Behçet's uveitis: road to remission

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Cytokines in autoimmune uveitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Tocilizumab for the treatment of steroid refractory graft-versus-host disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Human FoxP3+ regulatory T cells in systemic autoimmune diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

IL-6: regulator of Treg/Th17 balance

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Interleukin-6: from basic science to medicine--40 years in immunology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Interleukin-6 in biology and medicine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Interleukin-6 and the acute phase response

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Refractory uveitis in patient with castleman disease successfully treated with tocilizumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

31 May 2018

1 reference

Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

21 January 2018

1 reference

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review

21 January 2018

1 reference

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

Treatment of relapsing polychondritis with tocilizumab

21 January 2018

1 reference

Effective control of polymyalgia rheumatica with tocilizumab.

21 January 2018

1 reference

Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab

21 January 2018

1 reference

Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis.

21 January 2018

1 reference

Tocilizumab treatment for refractory uveitis-related cystoid macular edema.

21 January 2018

1 reference

Successful treatment with tocilizumab in a case of Cogan's syndrome complicated with aortitis.

21 January 2018

1 reference

Increased serum interleukin-17 in Graves' ophthalmopathy.

21 January 2018

1 reference

Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan

21 January 2018

1 reference

Tocilizumab treatment for recalcitrant uveitic macular edema

21 January 2018

1 reference

Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report

21 January 2018

1 reference

T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008973

Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma

28 November 2018

1 reference

12 December 2020

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

1 reference

12 December 2020

Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease

1 reference

12 December 2020

Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis

1 reference

12 December 2020

Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?

1 reference

12 December 2020

Therapeutic effect of tocilizumab on two patients with polymyositis

1 reference

12 December 2020

CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity

1 reference

12 December 2020

Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab

1 reference

12 December 2020

Biologic therapies and pregnancy: the story so far

1 reference

12 December 2020

Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis

1 reference

12 December 2020

Refractory neuro-Behçet treated by tocilizumab: a case report

1 reference

12 December 2020

The biology of interleukin-6

1 reference

12 December 2020

Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus

1 reference

12 December 2020

Interleukin-6 is a potent thrombopoietic factor in vivo in mice

1 reference

12 December 2020

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses

1 reference

12 December 2020

Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus

1 reference

12 December 2020

Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy

1 reference

12 December 2020

The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells

1 reference

12 December 2020

IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells

1 reference

12 December 2020

Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses

1 reference

12 December 2020

Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases

1 reference

12 December 2020

release_cvb3l3ablbc7rdzhmegylin54m

Identifiers

DOI

10.1111/CEI.12295

0 references

Fatcat ID

0 references

1 reference

PubMed publication ID

24528300

1 reference